About Alveron Pharma
Alveron Pharma is a company based in Nijmegen (Netherlands) founded in 2019. Alveron Pharma has raised $11.79 million across 3 funding rounds from investors including Rijksdienst voor Ondernemend Nederland, Oost NL and Thuja Capital. Alveron Pharma offers products and services including OKL-1111. Alveron Pharma operates in a competitive market with competitors including Hemab, Basking Biosciences, Acticor Biotech, Varmx and Remedy Pharmaceuticals, among others.
- Headquarter Nijmegen, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.79 M (USD)
in 3 rounds
-
Latest Funding Round
$4.51 M (USD), Series A
Oct 07, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alveron Pharma
Alveron Pharma offers a comprehensive portfolio of products and services, including OKL-1111.
Rapid treatment for haemorrhagic stroke to improve outcomes.
People of Alveron Pharma
Unlock access to complete
Funding Insights of Alveron Pharma
Alveron Pharma has successfully raised a total of $11.79M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $4.51 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alveron Pharma
Alveron Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Rijksdienst voor Ondernemend Nederland, Oost NL and Thuja Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage centric life sciences focused VC firm funding in Netherlands, Belgium and the US
|
Locked | Locked | Locked | |
|
Waterman Ventures is focused on supporting innovative growing businesses.
|
Locked | Locked | Locked | |
|
Sector-agnostic VC firm investing in geographies such as the Netherlands
|
Locked | Locked | Locked |
Investor details for Alveron Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alveron Pharma
Investment portfolio details for Alveron Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alveron Pharma
Detailed financials for Alveron Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alveron Pharma Comparisons
Peer comparison for Alveron Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alveron Pharma
Alveron Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemab, Basking Biosciences, Acticor Biotech, Varmx and Remedy Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Preventative therapies for rare bleeding and thrombotic disorders are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for ischemic stroke treatment are developed.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies.
|
|
| Locked | Locked | Locked |
Therapeutic proteins are developed to restore blood clotting in patients.
|
|
| Locked | Locked | Locked |
Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury.
|
|
| Locked | Locked | Locked |
Oral iron chelators are developed for iron overload disease treatment.
|
Detailed competitors of Alveron Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alveron Pharma
Complete news archive for Alveron Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alveron Pharma
Alveron Pharma was founded in 2019.
Alveron Pharma is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Alveron Pharma is a funded company, having raised a total of $11.79M across 3 funding rounds to date.
Alveron Pharma was founded in 2019 and is based in Nijmegen, Netherlands. Operations are centered in the pharmaceutical sector, where treatments for haemorrhagic stroke and intracranial haemorrhage are developed. Emphasis is placed on OKL-1111, a drug advanced as a rapid first-line therapy for intracranial hemorrhage. Research and development efforts are conducted to address these neurological conditions.
Alveron Pharma's top competitors include Acticor Biotech, Varmx and Remedy Pharmaceuticals.
Alveron Pharma offers OKL-1111.
Alveron Pharma has 4 investors. Key investors include Rijksdienst voor Ondernemend Nederland, Oost NL, Thuja Capital, and Waterman Ventures.